[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604610":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":24,"id":51,"slug":24,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":24,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":24,"enrollmentInfo":59,"targetDuration":24,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vitrectomy + Direct Intra-Arterial Microneedle Thrombolysis + Standard Care","EXPERIMENTAL","The patients will receive standard pars plana vitrectomy (PPV) combined with direct intra-arterial microneedle thrombolysis under microscopic visualization, in addition to standard clinical treatment for RAO. A 47G microneedle will be used to deliver thrombolytic agent intra-arterially per protocol.",[13],"Procedure: Standard Clinical Care Only",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Clinical Care Only","ACTIVE_COMPARATOR","The patients will receive standard clinical treatment for RAO without vitrectomy or intra-arterial microneedle thrombolysis.",[19],"Procedure: Vitrectomy + Direct Intra-Arterial Microneedle Thrombolysis + Standard Care",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"PROCEDURE",[15],null,{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[9],[28],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"Jian Ma, MD.","CONTACT","+8618858299889","jian_ma@zju.edu.cn",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Eye Center of the Second Affiliated Hospital of Zhejiang University","RECRUITING","Hangzhou","Zhejiang","310058","China",{"type":42,"coordinates":43},"Point",[44,45],120.16142,30.29365,{"lat":45,"lon":44},[48],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},{"type":50,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100604610",false,"NCT07151755","Microneedle Intra-Arterial Injection for Retinal Artery Occlusion","Microneedle Intra-Arterial Injection With Pars Plana Vitrectomy for Acute Retinal Artery Occlusion: A Prospective Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years\n* Acute non-arteritic retinal artery occlusion (RAO), including: Central retinal artery occlusion (CRAO), or Branch retinal artery occlusion (BRAO) involving the macula or causing severe visual loss; defined as symptom onset ≤7 days and confirmed by exam ± imaging (FFA\u002FOCT)\n* Best-corrected visual acuity (BCVA) \\\u003C0.5 (decimal)\n\nExclusion Criteria:\n\n* Active bleeding disorder, or significant bleeding within the past 3 months, or bleeding diathesis\n* Severe hypertension: SBP \\>185 mmHg or DBP \\>110 mmHg\n* Severe coagulopathy or ongoing therapeutic anticoagulation\n* Ischemic stroke within the past 3 months\n* Severe, unstable systemic disease rendering surgery or anesthesia risk unacceptable\n* Known hypersensitivity to thrombolytic agents or any study medications\u002Fmaterials\n* Active ocular infection\n* Vitreous hemorrhage\n* Retinal arteritis\n* Pregnancy or lactation","ALL","18 Years",{"count":60,"type":61},24,"ESTIMATED","INTERVENTIONAL",[64],"NA","This prospective interventional study evaluates the efficacy and safety of direct intra-arterial microneedle injection combined with pars plana vitrectomy for acute retinal artery occlusion (including central retinal artery occlusion \\[CRAO\\] and branch retinal artery occlusion \\[BRAO\\] involving the macula or causing severe visual loss). The primary endpoint is best-corrected visual acuity (BCVA, LogMAR) at 1 month. Secondary objectives include assessing the effect of treatment timing and monitoring longitudinal changes in visual function and retinal structure over 12 months.",[67],"Central Retinal Artery Occlusion",[69,70,71],"central retinal artery occlusion","microneedle","thrombolysis","2025-08-25",{"date":74,"type":75},"2025-09-03","ACTUAL",{"date":77,"type":61},"2025-09-01",{"date":79,"type":61},"2027-07-31",{"name":5,"class":6},1]